Holen Sie sich die Stockscreener-App
33.23
0.21%
0.07
Handel nachbörslich:
33.48
0.25
+0.75%
Schlusskurs vom Vortag:
$33.16
Offen:
$33.07
24-Stunden-Volumen:
742.86K
Relative Volume:
0.33
Marktkapitalisierung:
$4.05B
Einnahmen:
$1.24B
Nettoeinkommen (Verlust:
$209.00M
KGV:
20.01
EPS:
1.6605
Netto-Cashflow:
$-94.86M
1W Leistung:
+1.62%
1M Leistung:
+15.42%
6M Leistung:
+32.23%
1J Leistung:
+208.83%
1-Tages-Spanne:
$32.76
$33.28
1-Wochen-Bereich:
$32.02
$33.70
52-Wochen-Spanne:
$10.52
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Firmenname
Indivior Pharmaceuticals Inc
Sektor
Telefon
804-379-1090
Adresse
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
33.23 | 4.04B | 1.24B | 209.00M | -94.86M | 1.6605 |
TAK
Takeda Pharmaceutical Co Adr
|
16.63 | 52.60B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.87 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.58 | 42.40B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 36.34B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
567.16 | 25.11B | 3.18B | 1.33B | 1.04B | 27.90 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-22 | Fortgesetzt | Jefferies | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-23 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-03 | Eingeleitet | Craig Hallum | Buy |
| 2023-07-13 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Indivior Pharmaceuticals Inc Aktie (INDV) Neueste Nachrichten
Indivior (INDV) Showcases Research on Buprenorphine at Addiction Medicine Conference - GuruFocus
Indivior Pharmaceuticals Collaborates with Virginia Tech on Research Highlighting Remission and Treatment Outcomes in Opioid Use Disorder at ASAM Conference - Quiver Quantitative
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder - ChartMill
Indivior plans $400M convertible senior notes offering - MSN
Down 12.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Indivior Pharmaceuticals Inc. (INDV) - MSN
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
A Look at Indivior Pharmaceuticals Inc (INDV) After 3.6% Gain -- GF Value $21.89 vs Price $33.39 - GuruFocus
Does Indivior (INDV) Survey Support For Long-Acting Buprenorphine Strengthen Its Criminal Justice Strategy? - Sahm
Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates - Eastern Progress
Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.1% -- What GF Score of 69 Tells Investors - GuruFocus
Indivior Pharmaceuticals (INDV) Valuation Check After Recent Share Price Volatility - Yahoo Finance
Indivior PLC Survey Highlights Correctional Leaders' Support for Long-Acting Injectable Buprenorphine to Mitigate MOUD Diversion - Quiver Quantitative
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse - GlobeNewswire
INDV Insider Filing: Barry Patrick Restricted Stock Units April 2026 - Meyka
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug - The Globe and Mail
Assessing Indivior (INDV) Valuation After New SUBLOCADE Study In Correctional Healthcare - Sahm
Cipher Mining Stock, Five Below, Indivior Among 10 New Stocks On IBD Watchlists - Investor's Business Daily
A Look at Indivior Pharmaceuticals Inc (INDV) After 3.5% Gain -- GF Value $21.93 vs Price $31.60 - GuruFocus
Has The Strong Three-Year Run Left Indivior Pharmaceuticals (INDV) Priced Too Richly Today? - Yahoo Finance
How does Indivior Pharmaceuticals (INDV) Stock perform in rallies | INDV Q4 Earnings: Beats Estimates by $0.13Pre Announcement - Cổng thông tin điện tử Tỉnh Sơn La
How much upside is left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street analysts think 45.99% - MSN
Indivior Lends Voice to Help Raise Awareness of Substance Use Di - GuruFocus
If You Invested $1,000 in Indivior Pharmaceuticals Inc. (INDV) - Stock Titan
Indivior Pharmaceuticals Inc (INDV) Stock Down 5.5% but Still Ov - GuruFocus
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results - TradingView — Track All Markets
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200 - TradingView
How Much Upside is Left in Indivior Pharmaceuticals Inc. (INDV)? Wall Street Analysts Think 45.99% - Yahoo Finance
Indivior to Report Q1 2026 Earnings, Host Webcast - National Today
Indivior to Report First Quarter 2026 Financial Results - National Today
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th - The Manila Times
Indivior investors get Q1 results at 7 a.m., webcast at 8 a.m. EDT - Stock Titan
Is Indivior Pharmaceuticals (INDV) Stock Breaking Out | Price at $30.47, Up 0.16%Street Ratings - UBND thành phố Hải Phòng
Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView
Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - zacks.com
Is Indivior Pharmaceuticals (INDV) Stock Gaining Momentum | Price at $30.63, Up 0.53%Stock News - Xã Châu Thành
INDV Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
INDV | Indivior Pharmaceuticals, Inc. Common Executive Compensation - Quiver Quantitative
INDV Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
INDV Technical Analysis & Stock Price Forecast - Intellectia AI
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After New SUBLOCADE Cost Savings Evidence In Corrections Settings - Sahm
Indivior Pharmaceuticals Inc. R (E7P.F) Insider Ownership & Holdings - Yahoo! Finance Canada
JPMorgan Chase & Co. Has $5.01 Million Holdings in Indivior PLC $INDV - MarketBeat
Did Potential Jail Staffing Efficiencies From SUBLOCADE® Just Shift Indivior Pharmaceuticals' (INDV) Investment Narrative? - Sahm
Indivior Pharmaceuticals, Inc. (INDV) stock price, news, quote and history - Yahoo Finance UK
Small Cap Index Trust's Indivior Pharmaceuticals Inc(INDV) Holding History - GuruFocus
Indivior Pharmaceuticals Inc. R (E7P.F) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
Indivior Pharmaceuticals, Inc. (INDV) Stock forecasts - Yahoo Finance UK
Is Indivior Pharmaceuticals (INDV) Stock Good for Portfolio | Price at $30.47, Down 0.59%Verified Analyst Reports - Xã Châu Thành
What Indivior Pharmaceuticals (INDV)'s Prison Cost Model Findings Mean For Shareholders - Yahoo Finance
Indivior Pharmaceuticals, Inc. (INDV) Stock Forecasts - finance.yahoo.com
Finanzdaten der Indivior Pharmaceuticals Inc-Aktie (INDV)
Umsatz
Nettogewinn
Free Cashflow
ENV
Indivior Pharmaceuticals Inc-Aktie (INDV) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kingsley Stuart A | Director |
Mar 06 '26 |
Buy |
31.86 |
940 |
29,953 |
5,582 |
| Ryan Barbara | Director |
Mar 09 '26 |
Buy |
32.56 |
31 |
1,009 |
5,716 |
| Ryan Barbara | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
1,963 |
| Humphreys Keith | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
5,802 |
| NINIVAGGI DANIEL A | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,923 |
| Stejbach Mark | Director |
Jan 05 '26 |
Buy |
35.39 |
775 |
27,429 |
16,847 |
| Wheadon David E. | Director |
Jan 05 '26 |
Buy |
35.39 |
1,771 |
62,680 |
14,395 |
1.61%
1.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):